In November 2025, the U.S. Food and Drug Administration did something that quietly reshaped menopause care: it began removing the decades-old "black box" warning from menopausal hormone therapy products. If you have spent years being told that hormone therapy is too dangerous to consider, this is a genuine reason to reopen that conversation. It is also widely misunderstood. Because Menova sells no hormones and has nothing to gain from your decision either way, here is the plain-English version: what changed, what did not, and what to actually do with it.

What the FDA changed in 2025

On November 10, 2025, the Department of Health and Human Services and the FDA announced they would remove the boxed warning language about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products. The FDA approved the first labeling changes for six products, more than two dozen drug companies submitted proposed updates, and the changes took effect in early 2026. New labels are being rewritten with age-specific guidance.

What the FDA did not change

It is just as important to understand what did not change. The FDA did not remove every warning. The boxed warning about endometrial (uterine lining) cancer remains for products that contain systemic estrogen alone. And removing a warning from a label is not the same as declaring hormone therapy risk-free or right for everyone. It is a change in how the risks are described, not a clean bill of health.

Why the FDA removed the warning

Why did the agency change its position? Much of the original alarm came from the Women's Health Initiative studies in the early 2000s. One detail mattered enormously and was rarely mentioned: the average participant in those trials was about 63 years old, well past the typical age menopause begins, which is around 51. When researchers looked specifically at women who started hormone therapy within roughly ten years of menopause, in their 50s, the benefit and risk picture looked very different. For many of those women, the benefits of estrogen therapy outweighed the risks. The FDA concluded that the old blanket warnings had distorted that picture and discouraged women who might have benefited.

What the FDA change means for you

So what does this mean for you? If a clinician once told you hormone therapy was off the table, this update is a legitimate reason to ask again, especially if you are in perimenopause or early menopause and symptoms are interfering with your life. But "the warning was removed" is not the same as "you should take it." Your personal history still matters. A history of breast cancer, blood clots, or certain cardiovascular conditions can change the calculation, and the endometrial-cancer consideration still applies to estrogen-alone products. This is a decision for you and a licensed clinician, not a label and not a website.

You are probably hearing conflicting things, and there is a reason. Headlines compressed a nuanced change into slogans. Some say hormone therapy is now safe; others warn it is still dangerous. The honest answer sits in between and depends entirely on the individual. A company that sells hormones has a reason to oversell this moment. A cautious clinic has a reason to undersell it. We sell nothing, so we will say it plainly: this is a meaningful, evidence-based update that widens the door for many women, and it still requires a real, individualized conversation.

Questions to bring to your clinician

The most useful thing you can do with this news is to turn it into a better conversation with your own clinician. A few questions worth bringing:

  • Given my age and personal history, am I a candidate to start hormone therapy now?
  • Which of the risks on the old label actually apply to me?
  • What is the difference between FDA-approved and compounded hormone therapy for my situation?
  • If we try it, what will we watch for, and how will we know whether it is working?
  • If hormone therapy is not right for me, what are my non-hormonal options?

Walking in organized is what changes a ten-minute, dismissive appointment into a real discussion. If you want a simple way to lay out what you have been feeling before that visit, the free Menova self-check turns your symptoms into a plain-English summary you can bring with you. It is general education to help you prepare, not a diagnosis and not a recommendation to take any specific medication.

The label changed. Your next step is still a conversation, but now you can have it with the full picture instead of an outdated warning making the decision for you.

This article is general education, not medical advice. Always discuss your individual situation with a licensed clinician.

If you want to go deeper, a few widely respected, independent books on menopause are worth reading. (These are Amazon affiliate links — Menova may earn a small commission if you buy, at no extra cost to you. We sell no hormones and recommend these on editorial merit, not for commission.)

Sources: FDA / HHS announcement (Nov 2025), HHS fact sheet, and Harvard Health summary.